BDNF Loaded Amino Acid‐Catecholamine Hybrid Nanoparticles as Curative Agents Against Cognitive Decline in Alzheimer's Disease
Small · 2025
DOI: 10.1002/smll.202411701 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, 2025. Verfasst von Himanshu Sekhar Panda und 5 weiteren Autor:innen. Beteiligte Einrichtung: Brain and Supramolecular Nanotherapeutics Laboratory, Chemical Biology Unit, Institute of Nano Science and Technology, Sector-81, Knowledge City, Sah…. Hauptthemen laut MEDLINE: Alzheimer Disease, Nanoparticles, Cognitive Dysfunction, Brain-Derived Neurotrophic Factor. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 80 Literaturangaben. Gefördert von: SERB-POWER, Har Gobind Khorana-Innovative Young Biotechnologist Award, DBT grant.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer's disease (AD) is marked by the buildup of neurotoxic Aβ plaques.In this study, EGCG‐dopamine‐tryptophan nanoparticles (EDTNPs) that prevent Aβ fibrillization, aid plaque clearance, improve oxidative balance, reduce neuronal damage, and enhance cell survival through protective effects are synthesized. To boost neuroprotection further, BDNF, a neurotrophic factor that promotes neuronal growth, are loaded onto the EDTNPs (B‐EDTNPs), leading to a notable increase in the protection of neuronal cells. B‐EDTNPs exhibit a pronounced neuroprotective effect against FF and Aβ (1‐42) fibril‐induced toxicity in SH‐SY5Y neuroblastoma cells, enhancing cell viability from ≈ 37% to 92% and from 48% to 88%, respectively; which is ≈20% and ≈21% higher compared to EDTNPs at 24 h duration. Studies involving animal models further demonstrate that B‐EDTNPs effectively dislodge amyloid aggregates in vivo, leading to a significant reduction in plaque accumulation ( p < 0.001). This intervention not only promotes the clearance of toxic aggregates but also noticeably suppresses the NF‐κB and TNF‐α inflammatory biomarkers, aiding in restoring cognitive function and enhancing behavioral outcomes in treated BALB/c AD animal models. The theoretical studies show that NP components interact with Aβ (1–42) polypeptides, promoting disaggregation. This highlights a novel approach for creating effective nanocomposites that combine Aβ inhibitors with antioxidants to target AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Brain and Supramolecular Nanotherapeutics Laboratory, Chemical Biology Unit, Institute of Nano Science and Technology, Sector-81, Knowledge City, Sahibzada Ajit Singh Nagar, Punjab, 140306, India.
- Laboratory of Molecular NeuroTherapeutics, Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Raebareli, Uttar Pradesh, 226002, India.
- Gujarat Biotechnology University, Gandhinagar, Gujarat, 382355, India.
ORCID-Profile: Himanshu Sekhar Panda, Jiban Jyoti Panda
Förderung
- SERB-POWER
- Har Gobind Khorana-Innovative Young Biotechnologist Award
- DBT grant
- CSIR extramural grant
- ICMR extramural grant
Zitieren
APA
Panda, H. S., Dhokne, M. D., Thakur, S., Singh, N., Datusalia, A. K., & Panda, J. J. (2025). BDNF Loaded Amino Acid‐Catecholamine Hybrid Nanoparticles as Curative Agents Against Cognitive Decline in Alzheimer's Disease. Small. https://doi.org/10.1002/smll.202411701
Vancouver
Panda HS, Dhokne MD, Thakur S, Singh N, Datusalia AK, Panda JJ. BDNF Loaded Amino Acid‐Catecholamine Hybrid Nanoparticles as Curative Agents Against Cognitive Decline in Alzheimer's Disease. Small. 2025. doi:10.1002/smll.202411701
BibTeX
@article{Panda2025,
author = {Panda, Himanshu Sekhar and Dhokne, Mrunali D and Thakur, Sumit and Singh, Nisha and Datusalia, Ashok Kumar and Panda, Jiban Jyoti},
title = {BDNF Loaded Amino Acid‐Catecholamine Hybrid Nanoparticles as Curative Agents Against Cognitive Decline in Alzheimer's Disease},
journal = {Small},
year = {2025},
doi = {10.1002/smll.202411701}
}
EUVIMED